<SEC-DOCUMENT>0001193125-19-071917.txt : 20190312
<SEC-HEADER>0001193125-19-071917.hdr.sgml : 20190312
<ACCEPTANCE-DATETIME>20190312160533
ACCESSION NUMBER:		0001193125-19-071917
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20190306
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20190312
DATE AS OF CHANGE:		20190312

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			INOVIO PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0001055726
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				330969592
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-14888
		FILM NUMBER:		19675121

	BUSINESS ADDRESS:	
		STREET 1:		6769 MESA RIDGE RD.
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		8584103134

	MAIL ADDRESS:	
		STREET 1:		6769 MESA RIDGE RD.
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INOVIO BIOMEDICAL CORP
		DATE OF NAME CHANGE:	20050404

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GENETRONICS BIOMEDICAL CORP
		DATE OF NAME CHANGE:	20011116

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GENETRONICS BIOMEDICAL LTD
		DATE OF NAME CHANGE:	19980213
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d630823d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, DC 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">8-K</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT
REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to Section&nbsp;13 or 15(d) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>of the Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported): March&nbsp;6, 2019 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Inovio Pharmaceuticals, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">001-14888</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">33-0969592</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(IRS Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>660 W. Germantown Pike, Suite 110 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Plymouth Meeting, PA 19462 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive offices, including zip code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(267) <FONT STYLE="white-space:nowrap">440-4200</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Registrant&#146;s telephone number, including area code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former name or
former address, if changed since last report) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below
if the Form <FONT STYLE="white-space:nowrap">8-K</FONT> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Soliciting material pursuant to Rule <FONT STYLE="white-space:nowrap">14a-12</FONT> under the Exchange Act (17
CFR <FONT STYLE="white-space:nowrap">240.14a-12)</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to Rule <FONT
STYLE="white-space:nowrap">14d-2(b)</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.14d-2(b))</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to Rule <FONT
STYLE="white-space:nowrap">13e-4(c)</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.13e-4(c))</FONT> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this
chapter) or Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Securities Exchange Act of 1934 <FONT STYLE="white-space:nowrap">(&#167;240.12b-2</FONT> of this chapter). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;13(a) of the Exchange
Act.&nbsp;&nbsp;&#9744; </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of
Principal Officers. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>(b) Termination of Dr.&nbsp;Mark Bagarazzi as Chief Medical Officer </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&nbsp;6, 2019, Inovio Pharmaceuticals, Inc. (the &#147;Company&#148;) notified its Chief Medical Officer, Dr.&nbsp;Mark Bagarazzi, that his employment
with the Company would be terminated, effective as of April&nbsp;5, 2019. Upon such notice, his service as an executive officer of the Company ceased immediately. In connection with this termination, the Company has proposed to enter into a
separation agreement with Dr.&nbsp;Bagarazzi, which Dr.&nbsp;Bagarazzi may consider for a period required by law. If executed, the material terms of the separation agreement will be described as required in the Company&#146;s filings with the
Securities and Exchange Commission, and the separation agreement would be filed as an exhibit to the Company&#146;s quarterly report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-Q</FONT> for the quarter ending March&nbsp;31, 2019. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company also expects to enter into a consulting agreement with Dr.&nbsp;Bagarazzi pursuant to which he would provide consulting services to the Company
for a specified period of time following the termination of his employment. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>(c) Appointment of Jacqueline E. Shea, Ph.D., as Chief Operating Officer
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&nbsp;8, 2019, the Company appointed Jacqueline E. Shea, Ph.D., as its new Chief Operating Officer. Dr.&nbsp;Shea replaces the Company&#146;s
former Chief Operating Officer Dr.&nbsp;Niranjan Sardesai, who now serves as Chief Executive Officer of Geneos Therapeutics, Inovio&#146;s majority-owned subsidiary. Dr.&nbsp;Shea will begin service as the Company&#146;s principal operating officer
on March&nbsp;25, 2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to joining the Company, Dr.&nbsp;Shea, age 53, served as chief executive officer of Aeras, a nonprofit organization
developing tuberculosis vaccines, from August 2015 to December 2018, and as its chief operating officer from April 2014 to August 2015. Dr.&nbsp;Shea previously served as Vice President of Business Development, Europe for Emergent BioSolutions Inc.
from May 2013 to March 2014. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There are no arrangements or understandings between Dr.&nbsp;Shea and any other person pursuant to which she was selected as
an officer of the Company, and there is no family relationship between Dr.&nbsp;Shea and any of the Company&#146;s other directors or executive officers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has entered into an employment agreement with Dr.&nbsp;Shea that provides for an annual base compensation of $400,000, a <FONT
STYLE="white-space:nowrap">one-time</FONT> signing bonus of $35,000 and an annual bonus of up to 40% of her base salary. In addition, upon commencing employment with the Company, she will be granted an option to purchase 200,000 shares of common
stock and will also be granted 50,000 restricted stock units. The options will vest over a period of three years, with <FONT STYLE="white-space:nowrap">one-quarter</FONT> of the shares vesting on the date of grant and
<FONT STYLE="white-space:nowrap">one-quarter</FONT> of the shares vesting on each of the first, second and third anniversaries of the grant date. The restricted stock units will vest over a period of three years, with
<FONT STYLE="white-space:nowrap">one-third</FONT> of the shares vesting on each of the first, second and third anniversaries of the grant date. Vesting in each case is subject to Dr.&nbsp;Shea&#146;s continued service as an officer of the Company on
each vesting date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The terms of Dr.&nbsp;Shea&#146;s employment also provide for certain severance benefits. If Dr.&nbsp;Shea is terminated other than on
account of death, total disability or for Cause (as defined in her employment agreement), or if Dr.&nbsp;Shea terminates her employment for Good Reason (as defined in her employment agreement), she will be entitled to any unpaid portion of her base
salary computed on a <FONT STYLE="white-space:nowrap">pro-rata</FONT> basis through the date of termination, any unreimbursed expenses, all other accrued but unpaid rights, a severance payment in the amount of 12 months of base salary and COBRA
payments for 12&nbsp;months following termination. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;7.01 Regulation FD Disclosure. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&nbsp;12, 2019, the Company issued a press release announcing an executive-level reorganization, including the appointment of Dr.&nbsp;Shea and the
termination of Dr.&nbsp;Bagarazzi.&nbsp;A copy of this press release is furnished herewith as Exhibit 99.1 to this Current Report. The information contained in the press release furnished as Exhibit 99.1 shall not be deemed &#147;filed&#148; for
purposes of Section&nbsp;18 of the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;), and is not incorporated by reference into any of the Company&#146;s filings under the Securities Act of 1933, as amended, or the Exchange
Act, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in any such filing. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;9.01
Financial Statements and Exhibits. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Exhibit<BR>No.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Exhibit Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d630823dex991.htm">Press Release, dated March&nbsp;12, 2019. </A></TD></TR>
</TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>INOVIO PHARMACEUTICALS, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: March&nbsp;12, 2019</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Peter Kies</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Peter Kies</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Financial Officer</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d630823dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g630823g82t59.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>CONTACTS: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%" VALIGN="top" ALIGN="left">Investors:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Ben Matone, Inovio,
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">484-362-0076,</FONT></FONT> <U>ben.matone@inovio.com</U> </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%" VALIGN="top" ALIGN="left">Media:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Jeff Richardson, Inovio,
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">267-440-4211,</FONT></FONT> <U>jrichardson@inovio.com</U> </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Inovio Appoints Chief Operating Officer; </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Announces Strategic Management Changes </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">PLYMOUTH MEETING, PA &#150; March&nbsp;12, 2019 &#150; Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today the appointment of Jacqueline E. Shea, PhD,
as Inovio&#146;s Chief Operating Officer (COO) and Executive Vice President. Dr.<U></U>&nbsp;Shea is an experienced life sciences senior executive with an extensive track record of leadership, strategy development, operational management, product
development and international corporate development achievements. She most recently served as CEO and COO of Aeras, the leading <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">not-for-profit</FONT></FONT> organization dedicated to
developing new tuberculosis vaccines. At Inovio, Dr.&nbsp;Shea will be responsible for Inovio&#146;s manufacturing, commercial, business development, and alliance management operations as well as serving as a key member of the executive team along
with CFO and CSO in formulating and implementing overall corporate strategy. Dr.&nbsp;Shea replaces Dr.<U></U>&nbsp;Niranjan&nbsp;Y. Sardesai who now serves as Chief Executive Officer of Geneos Therapeutics, a
<FONT STYLE="white-space:nowrap">spin-out</FONT> of Inovio developing personalized cancer treatments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Across the board, Inovio has taken steps to
streamline its management responsibilities to better align comprehensive development strategy from discovery to commercialization. Effective immediately, Inovio&#146;s global clinical and R&amp;D functions will report to Dr.&nbsp;Laurent Humeau,
Inovio&#146;s Chief Scientific Officer and Executive Vice President. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a part of this realignment, Dr.&nbsp;Mark Bagarazzi, formerly Chief Medical
Officer, has left the company. In place of the Chief Medical Officer position, Inovio&#146;s newly formed Medical Council will oversee all clinical studies and medical-related reporting and monitoring activities and will report to
Dr.<U></U>&nbsp;Humeau. Inovio&#146;s Medical Council comprises three of Inovio&#146;s current Vice Presidents of Clinical Development: Prakash Bhuyan, MD (HPV program); Jeffrey Skolnik, MD, (cancer); and Scott White, MD (infectious diseases). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;J. Joseph Kim, Inovio&#146;s President and CEO, said, &#147;This strategic reorganization will improve execution of current clinical programs and
provide the management alignment to seamlessly connect new product research to commercial product candidates. Drs. Shea and Humeau are accomplished industry executives who have demonstrated their leadership qualities and delivered commercial
results. In addition, the three physicians who make up our Medical Council have deep expertise in the global clinical development of Inovio&#146;s major therapeutic areas of cancer, infectious disease and our lead program devoted to HPV
diseases.&#148;<U></U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Shea said, &#147;I am excited by Inovio&#146;s proven development platform and clinical pipeline and its potential to
address major diseases across cancer and infection. In addition to the vaccines and immunotherapies that are in the clinic, I see the tremendous potential for the dMAb programs to drive significant value for the company and am delighted to join the
leadership team developing Inovio&#146;s portfolio of products.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to her role at Aeras, Dr.&nbsp;Shea held top management positions at two
biotechnology companies: Emergent Product Development UK (part of Emergent BioSolutions) and Microscience Ltd; and was general manager of The Oxford-Emergent Tuberculosis Consortium, a global health joint venture formed between Oxford University and
Emergent BioSolutions. She started her career as a post-doctoral researcher at Imperial College, London, where she contributed to the development of signature-tagged </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
mutagenesis which received a Prix Galien commendation for excellence in innovative research. She received her PhD from the National Institute for Medical Research and a BSc in Applied Biology
with First Class<U></U>&nbsp;Honors from University of Bath. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Inovio Pharmaceuticals, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Inovio is a late-stage biotechnology company focused on the discovery, development, and commercialization of <FONT STYLE="white-space:nowrap">DNA-based</FONT>
immunotherapies and vaccines that transform the treatment and prevention of cancer and infectious disease. Inovio&#146;s proprietary technology platform applies antigen sequencing and DNA delivery to activate potent immune responses to targeted
diseases. The technology functions exclusively in vivo, and has been demonstrated to consistently activate robust and fully functional T cell and antibody responses against targeted cancers and pathogens. Inovio&#146;s most advanced clinical
program, <FONT STYLE="white-space:nowrap">VGX-3100,</FONT> is in Phase 3 for the treatment of <FONT STYLE="white-space:nowrap">HPV-related</FONT> cervical <FONT STYLE="white-space:nowrap">pre-cancer.</FONT> Also in development are Phase 2
immuno-oncology programs targeting <FONT STYLE="white-space:nowrap">HPV-related</FONT> cancers, bladder cancer, and glioblastoma, as well as platform development programs in hepatitis B, Zika, Ebola, MERS, and HIV. Partners and collaborators include
AstraZeneca, Regeneron, Roche/Genentech, ApolloBio Corporation, The Wistar Institute, The Bill&nbsp;&amp; Melinda Gates Foundation, the University of Pennsylvania, Parker Institute for Cancer Immunotherapy, CEPI, DARPA, GeneOne Life Science,
Plumbline Life Sciences, NIH, HIV Vaccines Trial Network, National Cancer Institute, U.S. Military HIV Research Program, Drexel University, and Laval University. For more information, visit <U>www.inovio.com</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"># # # # </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>This press release contains certain
forward-looking statements relating to our business, including Dr.&nbsp;Shea&#146;s responsibilities, the role of our newly formed Medical Council and anticipated benefits of our strategic reorganization. Actual events or results may differ from the
expectations set forth herein as a result of a number of factors, including our ability to successfully implement the strategic reorganization and effectively integrate and transition changes in management, our ongoing business needs and other
factors set forth in our Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarter ended September&nbsp;30, 2018 and other regulatory filings we make from time to time. There can be no assurance that any product candidate
in our pipeline will be successfully developed, manufactured or commercialized, that final results of clinical trials will be supportive of regulatory approvals required to market licensed products, or that any of the forward-looking information
provided herein will be proven accurate. Forward-looking statements speak only as of the date of this release, and we undertake no obligation to update or revise these statements, except as may be required by law. </I></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g630823g82t59.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g630823g82t59.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M-QM?-K:DPPCMP>3^)_I3 [7X6^#84LT\07\0>:0_Z,C#(0?WOJ>U(#U*@ H
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MBW!;W()'\L4P-_X+7#-I^K6Q/RQR1N/JP(/_ *"*0'1?$W_D0K_ZQ_\ H8H
M\>\!_P#(\:3_ -=OZ&F!](4@,OQ)_P BOJO_ %Z2_P#H!H ^:;'_ )"%O_UU
M7^=,1]54AA0!@^-O^1*UC_KV:@#Y\T#_ )&/3/\ KZC_ /0A3$?4-(9Y+\9K
M=Q-I-R!\FUT)]#D&O:RN6DHGB9K'6,CC/ LR0>-M)>0X7SMOXD$#]37=BTW0
MDD<&#:5>-^Y]&U\N?5!0 4 % !0!Y1\8=9!^Q:+&>1_I$GZA1_/]*]G+*6]1
M^AXN:5=J:]3SOP[IKZMXAL;%%SYLJAO9>I/Y9KTZTU3IN1Y="FZE2,4?38
MP. *^3/K@H ^>/B'H']@^*IQ$FVUNOWT6.@SU'X'/Z4P.@\+>.AI?P]U&T>7
M%Y:_+:@GDA^F/]TY/Y4 <#I.G3ZSK%M80Y,MQ(%SZ>I_ 9- CZ=L+*'3K"WL
MK==L,"!%'L!2&6* "@#Y>\0?\C)JG_7W+_Z&:8CZ"\$_\B3H_P#U[K2&;%];
M_:M/N;;_ )ZQ,GYC% 'RPZO;SLC#:\;8(/8BF(^H=(OH]3T>SOHFRL\2O^)'
M(_.D,NT % !0!X3\6M02[\7K;QD$6D"QMC^\<L?YBF!U/P8LVCTC4KP@A9IE
M0>^T$_\ LU(#>^)O_(A7_P!8_P#T,4 >/> _^1XTG_KM_0TP/I"D!E^)/^17
MU7_KTE_] - 'S38_\A"W_P"NJ_SIB/JJD,* ,'QM_P B5K'_ %[-0!\^:!_R
M,>F?]?4?_H0IB/J&D,YSQOX>/B/PW-:Q ?:HCYL&>[#M^(R*ZL)6]C43>W4Y
M,70]M2<5OT/GD&:SN@?FBGA?OP58'_&OIM)+R/F-8OS1]%>$?$UOXFT:.Y1E
M%R@"SQ=U;U^A[5\QB:#H3MTZ'U.&Q"KPNM^IOUS'2% !0 4 <5XM\$V7C"Z%
MQ!=FWNX!Y;2!=R-_LGD<C-=^&Q4L.K-73//Q.$CB7=.S1+X/\ 6GA:9[MK@W
M5ZR[0Y7:J#O@?UI8G&2KKEM9#PN"CAWS7NSL*X3O"@#BOB=H']L>%WN8DS<V
M.95QU*_Q#\N?PH \"IB/5O@]H&Z2YUV9.%_<P9]?XC_(?B:!GKE( H * /E[
MQ!_R,FJ?]?<O_H9IB/H+P3_R).C_ /7NM(9OT >"_$[PV^C^(GOXD_T.^8NI
M X5_XA_7\?:F!H_#;QW#HZ_V-JDFRS9LPS'I&3U!]C^E 'L\<B2QJ\;JZ,,A
ME.012 =0!R_B_P :V/A>R==ZS:@R_NH <D'U;T'\Z / 0+S6]6X#3WEW+^+,
M33$?2'AK14\/^'[334(+1+EV'\3GEC^=(9C?$W_D0K__ 'H__0Q0!X_X#_Y'
MC2?^NW]#3 ^CZ0&7XD_Y%?5O^O27_P! - 'S38_\A"W_ .NJ_P Z8CZJI#"@
M#!\;?\B5K'_7NU 'SYH'_(Q:9_U]1_\ H0IB/J&D,* .&\9_#NV\0LU]8LMM
MJ./FS]R7Z^A]Z]#"XUT?=EJOR/.Q6!C6]Z&C_,\K\CQ'X(U59S%-9S*<!\91
MQZ9Z,*]B]'$PMNCQ;5L+.^S/0M%^+UC+&L>L6KV\H',D(W(?PZC]:\VKELD[
MTW<]2EF<6K5%8Z:/X@>%I$W#5XP/1D8'^5<CP5=?9.Q8W#O[15G^)/A]7$5D
M]QJ$Y^[';0L23^.*M8&MO+1>9#Q]':.K\D6;<:_KV&O4.CZ>?^6*-FXD'H6_
M@'TY^E1+V5'X?>?X?\$N/MJWQ>ZOQ_X!T4$$5K D$$:QQ(,*JC@"N5MR=V=2
M2BK(DI#"@ H 1E5U*L 5(P0>] 'SEXG\,3Z5XQETBWC+":0&V']Y6/RC\.GX
M4Q'OVAZ5%H>B6FG0XVP(%)_O-W/XG-(9H4 % !0!\O\ B#_D9-4_Z^Y?_0S3
M$?0/@G_D2='_ .O=:0S?H HZOI%GKFFRV%]%YD,@_%3V(/8B@#PCQ3\/]6\.
M2O+'&UW89RL\:YVC_:';^5,#'TSQ+K6C+LT_4IX$_N!LK^1XH$7KCQ[XHN8C
M')K$X4\'9A#^8 - S,T_2]3UZ^\JSMYKJ=SEB.<>Y)Z?4T"/:_ W@"#PR@O;
MPK/J;+C(Y6(>B^_O2&=O0 R2*.9"DJ*Z'JK#(H B2PLXG#QVD*..A6, B@"Q
M0 C*KJ58 J1@@C@T 5QIUB""+* $?],E_P * +- !0 UT21"CJ&4\$$9!H @
M73[)&#+9P!@<@B,<4 6: "@ H 9+%'-&8Y8U=#U5AD'\*:;6J$TFK,PKKP-X
M9O&+2Z/ ">\>4_\ 02*Z(XNO':1S2P="6\2"+X>>%8FW#248_P"U(Y'Y$U3Q
MM=_:)6!PZ^R;ECI=AIB;+&R@ME_Z91A<_E7/.I.?Q.YTPIPAI%6+=06% !0
M4 % !0!F7FA65[K=AJTR9N;(,(_0Y]?ISCZT := !0 4 % %9M/LF8LUG 6)
MR28QS0!.B)&@1%"J. %& * '4 % !0!BWWA#P]J3E[K2+9W/5E7:3^(Q0!4A
I^'_A6!]RZ/$3_MLS#\B: -^VM+:RA$-K;QP1#HL:!1^0H FH * /_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
